CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Jeet Mahal

Profile

Jeet Mahal

interim Principal Financial Officer, Jasper Therapeutics, Inc.

In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.

Jeet Mahal has been interim Principal Financial Officer of Jasper Therapeutics, Inc. since October 9, 2026, according to the company's filing of September 28, 2026.1

The filing gives Jeet Mahal's previous role as President and Chief Executive Officer at Jasper Therapeutics, Inc.1 Jeet Mahal already worked at Jasper Therapeutics, Inc. when appointed, so the record counts the move as an internal promotion.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Jasper Therapeutics, Inc. (JSPR)
Biological Products, (No Diagnostic Substances)
interim Principal Financial OfficerIn the seat, on an interim basis1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. October 9, 2026effective

    Jasper Therapeutics, Inc. named Jeet Mahal interim Principal Financial Officer, effective October 9, 2026. Profile of Herb Cross.

    [1] Filing by Jasper Therapeutics, Inc., filed with the SEC on September 28, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Jasper Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 28, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jeet Mahal wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.